Forward-Looking Statements

This presentation may contain certain "forward-looking statements" which are not historical facts, but instead are predictions about future events based on our beliefs as well as assumptions made by and information currently available to our management. Although we believe that our predictions are reasonable, future events are inherently uncertain and our forward-looking statements may turn out to be incorrect. Our forward-looking statements are subject to risks relating to, among other things, the ability of our service offerings to compete effectively, our ability to meet timelines for the expansion of our service offerings, our ability to protect our clients’ intellectual property, unforeseeable international tension, competition, the impact of emergencies and other force majeure. Our forward-looking statements in this presentation speak only as of the date on which they are made, and we assume no obligation to update any forward-looking statements except as required by applicable law or listing rules. Accordingly, you are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. All forward-looking statements contained herein are qualified by reference to the cautionary statements set forth in this section. All information provided in this presentation is as of the date of this presentation and are based on assumptions that we believe to be reasonable as of this date, and we do not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Non-IFRS Financial Measures

We provide non-IFRS gross profit and non-IFRS net profit attributable to owners of the Company, which exclude share-based compensation expenses, issuance expenses of convertible bonds, fair value gain or loss from derivative component of convertible bonds, foreign exchange-related gains or losses and amortization of intangible assets acquired in business combinations, non-financial assets impairment, etc. We also provide adjusted non-IFRS net profit attributable to owners of the Company and earnings per share, which further exclude realized and unrealized gains or losses from our venture capital investments and joint ventures. Neither of above is required by, or presented in accordance with IFRS.

We believe that the adjusted financial measures used in this presentation are useful for understanding and assessing our core business performance and operating trends, and we believe that management and investors may benefit from referring to these adjusted financial measures in assessing our financial performance by eliminating the impact of certain unusual, non-recurring, non-cash and non-operating items that we do not consider indicative of the performance of our core business. Such non-IFRS financial measures, the management of the Company believes, is widely accepted and adopted in the industry the Company is operating in. However, the presentation of these adjusted non-IFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with IFRS. You should not view adjusted results on a stand-alone basis or as a substitute for results under IFRS, or as being comparable to results reported or forecasted by other companies.

Disclaimer

All intellectual property rights and other rights pertaining to the information and materials presented in the results briefing are owned by WuXi AppTec Co., Ltd. (“WuXi AppTec” or the “Company”). Audio recording, video recording or disclosure of such materials by any means without the prior consent of WuXi AppTec is prohibited. This briefing does not intend to provide a complete statement of the relevant matters. For relevant information, please refer to the 2023 Third Quarterly Report published on the website of Hong Kong Stock Exchange (www.hkexnews.hk), Shanghai Stock Exchange (www.sse.com.cn) and media designated by the Company.
Note: All financials disclosed in this presentation are prepared based on International Financial Reporting Standards (or “IFRSs”). The currency is RMB. All net profit disclosed in this presentation represents net profit attributable to the owners of the Company.
1. Results Overview
Revenue in Q3 2023 Back to over RMB 10 Billion

<table>
<thead>
<tr>
<th></th>
<th>Q3 2022</th>
<th>Q3 2023</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenue</strong></td>
<td>10.6</td>
<td>10.7</td>
<td>+0.3%</td>
</tr>
<tr>
<td><strong>Adjusted Non-IFRS Net Profit</strong></td>
<td></td>
<td></td>
<td>+15.7%</td>
</tr>
<tr>
<td><strong>Net Profit</strong></td>
<td>2.7</td>
<td>2.8</td>
<td>+0.8%</td>
</tr>
<tr>
<td><strong>Net Profit After Deducting Non-Recurring Items</strong></td>
<td>2.4</td>
<td>2.9</td>
<td>+23.8%</td>
</tr>
</tbody>
</table>

Note: The non-recurring net profit is prepared according to the requirement of information disclosure rules issued by China Securities Regulatory Commission.
Continued Solid Growth of Revenue & Profit in Q1-Q3 2023

**Revenue**

<table>
<thead>
<tr>
<th></th>
<th>Q1-Q3 2022</th>
<th>Q1-Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>RMB billion</td>
<td>28.4</td>
<td>29.5</td>
</tr>
</tbody>
</table>

+4.0% excluding COVID-19 commercial projects

**Adjusted Non-IFRS Net Profit**

<table>
<thead>
<tr>
<th></th>
<th>Q1-Q3 2022</th>
<th>Q1-Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>RMB billion</td>
<td>6.8</td>
<td>8.2</td>
</tr>
</tbody>
</table>

+20.6%

**Net Profit**

<table>
<thead>
<tr>
<th></th>
<th>Q1-Q3 2022</th>
<th>Q1-Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>RMB billion</td>
<td>7.4</td>
<td>8.1</td>
</tr>
</tbody>
</table>

+9.5%

**Net Profit After Deducting Non-Recurring Items**

<table>
<thead>
<tr>
<th></th>
<th>Q1-Q3 2022</th>
<th>Q1-Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>RMB billion</td>
<td>6.2</td>
<td>7.7</td>
</tr>
</tbody>
</table>

+23.7%

Note: The non-recurring net profit is prepared according to the requirement of information disclosure rules issued by China Securities Regulatory Commission.
Q1-Q3 2023 Business Highlights

**Enable Customers to Grow Together**
- 900+ new customers, 6,000+ active customers
- Backlog maintained H1 growth momentum, among which: TIDES backlog accelerated to grow +245%↑
- Excluding COVID-19 commercial projects, revenue from Top20 pharma continued rapid growth +43%↑

**Small Molecule CRDMO Pipeline**
- 3,014 molecules, 926 newly added molecules, including 58 commercial, 61 Phase III
- Adding 12 commercial & Phase III projects
- Excluding COVID-19 commercial projects, D&M revenue grew +48%↑

**Cell & Gene Therapies CTDMO Pipeline**
- 7 Phase III, 9 Phase II, 52 Phase I & preclinical
- Advancing 4 potential commercial manufacturing projects

**Build Platform & Improve Efficiency**
- 32 global sites & branch offices
- 41,148 total employees, including 37,899 scientists & technicians
- Adding 55,000 m² testing laboratories, continued to advance the design & construction of facilities around the world
- Continued to improve operating efficiency.
- Adjusted non-IFRS GPM increased ~1pt YoY at CER, and operating cash flow grew +33%↑.
- Continued to invest in new capacities & new capabilities

**Development of DDSU Pipeline**
- 2 NDA approved, 2 in NDA review, 5 Phase III, 99 Phase II & Phase I
- 2 new drugs approved, continued to receive royalty income of the 2 new drugs approved from customers
Our Platform & Business Model Continued to Perform Well

**Strong, Loyal & Expanding Customer Base**

Revenue breakdown

- **Existing clients**
  - 29.12Bn, excluding COVID-19 commercial projects +26%↑

- **Newly added clients**
  - 0.43Bn

**Execute Long-Tail Strategy & Increase Support to Large Pharma**

Revenue breakdown

- **Top 20 global pharma clients**
  - 11.82Bn, excluding COVID-19 commercial projects +43%↑

- **Other clients**
  - 17.72Bn, +16%↑

**Increase Customer Conversion to Sustain Growth**

Revenue breakdown

- **Clients using multiple services**
  - 27.27Bn, excluding COVID-19 commercial projects +28%↑

- **Clients using single service**
  - 8%
Diversified Revenue Streams from Customers Across Regions Ensure the Stability and Resilience of the Company’s Financial Performance

US
19.40Bn, +36%
Revenue contribution: 66%
excluding COVID-19 commercial projects

Europe
3.28Bn, +10%
Revenue contribution: 11%

China
5.24Bn, +5%
Revenue contribution: 18%

Japan, Korea & Others
1.62Bn, +10%
Revenue contribution: 5%
ESG Leading Position Further Enhanced in the Global ESG Rating Systems

Consecutive “AA” ratings in 2021, 2022 and 2023

Improved to “Silver” rating in 2023

Named to the 2022 S&P DJSI (World and Emerging Markets)

Awarded as Industry and Regional Top Rated company

Leadership level of “A-” in 2022 CDP Climate Change rating
2. Business Highlights
WuXi Chemistry: Integrated CRDMO Business Model Drives Steady Growth, with Continued Expansion in TIDES

Financial Performance
- Q3 revenue declined 0.9% YoY to 7.77bn, excluding COVID-19 commercial projects, grew 22.4%
- Q1-Q3 revenue grew 2.0% YoY to 21.24bn, excluding COVID-19 commercial projects, grew strongly by 31.0%
- Q1-Q3 adjusted non-IFRS GPM 45.7%, improved by 4.5pts YoY, mainly due to FX impact, while efficiency continued to improve

Drug Discovery (R) Generating Downstream Opportunities
- In the past 12 months, successfully synthesized and delivered 420,000+ new compounds (grew 11% YoY), generating opportunities for downstream business units
- With strengthened capabilities of the integrated platform, molecules converted from R to D&M continued rapid growth
- Growing demand from long-tail customers in discovery services of small molecule & new modalities, # of new customers grew 12% YoY

Strong Growth of Development and Manufacturing (D&M)
- Q1-Q3 D&M revenue grew 1.4% YoY to 15.63bn; excluding COVID-19 commercial projects, grew strongly by 48.2%
- Total pipeline of 3,014 molecules (with 926 newly added in Q1-Q3), including 58 commercial, 61 Phase III, 316 Phase II, and 2,579 preclinical & Phase I projects, adding 12 commercial & Phase III projects in Q1-Q3

Continued Expansion of New Modalities (TIDES)
- Q1-Q3 TIDES revenue grew strongly by 38.1% YoY to 2.07bn. Q4 revenue expected to increase significantly, with TIDES full year revenue growth expected to exceed 60% in 2023. As of Sep. 30, 2023, TIDES backlog accelerated to grow by 245% YoY
- TIDES D&M customers grew 31% YoY to 127, and molecules grew 48% YoY to 230
- Initiated capacity expansion in Changzhou and Taixing. The expanded workshops are expected to commence operation in Dec. 2023, with the total reactor volume of peptide solid phase synthesizers increased from 20,000L to 32,000L

Revenue

<table>
<thead>
<tr>
<th></th>
<th>Q1-Q3 2022</th>
<th>Q1-Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q3</td>
<td>20.82</td>
<td>21.24</td>
</tr>
<tr>
<td>H1</td>
<td>7.84</td>
<td>7.77</td>
</tr>
<tr>
<td></td>
<td>+2.0%</td>
<td>+31.0%</td>
</tr>
</tbody>
</table>

Adjusted Non-IFRS Gross Profit

<table>
<thead>
<tr>
<th></th>
<th>Q1-Q3 2022</th>
<th>Q1-Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q3</td>
<td>3.26</td>
<td>3.61</td>
</tr>
<tr>
<td>H1</td>
<td>5.31</td>
<td>6.10</td>
</tr>
<tr>
<td></td>
<td>+10.8%</td>
<td>+14.9%</td>
</tr>
</tbody>
</table>
WuXi Chemistry: Growing CRDMO Pipeline driven by “Follow the Molecule + Win the Molecule” Strategies

Q1-Q3 2023 Newly Added Molecules in Total 926

428,269 Compounds

2,579 Preclinical & Phase I

316 Phase II

61 Phase III

58 Commercial

Note: 1. 428,269 compounds successfully synthesized in labs in the past 12 months.
WuXi Testing: Drug Safety Evaluation Service & SMO Maintain Leadership Position and Drive Steady Growth

### Financial Performance
- Q3 revenue grew **12.2%** YoY to **1.76bn**
- Q1-Q3 revenue grew **16.2%** YoY to **4.85bn**
- Q1-Q3 adjusted non-IFRS GPM **38.6%**, improved by **1.8pts** YoY, mainly due to FX impact, while efficiency continued to improve

### Lab Testing Services
- Q3 revenue of lab testing services grew **12.2%** YoY to **1.29bn**, among which, drug safety evaluation service revenue grew strongly by **31.5%** YoY
- Q1-Q3 revenue of lab testing services grew **16.3%** YoY to **3.54bn**, among which, drug safety evaluation service revenue grew **26.9%**, YoY, maintaining the APAC industry leadership position. Meanwhile, new facilities in Qidong and Suzhou have begun delivering new projects
- New modality capabilities continue to develop, while market share of nucleic acids, conjugates, and mRNA further expands, and new vaccine capabilities continue to improve

### Clinical CRO & SMO
- Q3 revenue from clinical CRO and SMO grew **12.0%** YoY to **0.47bn**, among which, SMO revenue grew by **25.8%** YoY
- Q1-Q3 revenue from clinical CRO and SMO grew **15.9%** YoY to **1.32bn**, among which, SMO revenue grew strongly by **31.0%** YoY, maintaining leadership position in China
- Clinical CRO enabled customers to obtain **13** IND approvals and submit for **5** NDA filings; SMO supported **35** new drug approvals

### Revenue

<table>
<thead>
<tr>
<th></th>
<th>Q1-Q3 2022</th>
<th>Q1-Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q3</td>
<td>4.18</td>
<td><strong>+16.2%</strong></td>
</tr>
<tr>
<td>H1</td>
<td>2.61</td>
<td><strong>+18.7%</strong></td>
</tr>
</tbody>
</table>

### Adjusted Non-IFRS Gross Profit

<table>
<thead>
<tr>
<th></th>
<th>Q1-Q3 2022</th>
<th>Q1-Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q3</td>
<td>0.61</td>
<td><strong>+15.4%</strong></td>
</tr>
<tr>
<td>H1</td>
<td>0.93</td>
<td><strong>+26.1%</strong></td>
</tr>
</tbody>
</table>

GPM @ CER:
- **37.2%** Q1-Q3 2022
- **37.6%** Q1-Q3 2023

**Adjusted Non-IFRS GPM**
Financial Performance

- Q3 revenue declined 3.8% YoY to 0.66bn
- Q1-Q3 revenue grew 6.5% YoY to 1.89bn
- Q1-Q3 adjusted non-IFRS GPM 42.8%, improved by 1.6pts YoY due to FX impact
- Q1-Q3 revenue from new modalities grew strongly by 35% YoY, contributing 25.9% of revenue

Discovery Biology

- One of the largest discovery biology enabling platforms with ~3,000 experienced scientists globally (across 9 sites in China, the US and Germany), covering all stages of drug discovery and all major therapeutic areas
- Focused on improving capabilities related to new modalities. Number of customers and projects served by our nucleic acid platform continued to increase. Cumulatively, we have provided services to 130+ customers, and successfully delivered 800+ projects since 2021

Comprehensive Screening Platform

- Early discovery screening platform integrating multi-technologies (HTS, DEL, ASMS, FBDD, CADD, etc.) and analysis capabilities of multi-dimensional databases, provides extensive and in-depth services to customers
- In Q3 2023, launched the automated high-throughput protein production in Suzhou, and DELvision, a new service of chemical-proteome database to bridge the gap between small molecule chemical space and proteomics. Through accumulation of the eminent experimental data, DELvision empowers customers to effectively decipher the mechanism of protein-small molecule interactions
- In Q1-Q3 2023, continued to generate downstream opportunities and contributed 20%+ of the Company’s new customers

WuXi Biology: New Modalities Business Drives Growth; WuXi Biology Platform Continues to Generate Downstream Opportunities

WuXi Biology:
New Modalities Business Drives Growth;
WuXi Biology Platform Continues to Generate Downstream Opportunities

Financial Performance

Relevant data points are as follows:

- **Q3 revenue decline**: 3.8% YoY to 0.66bn
- **Q1-Q3 revenue growth**: 6.5% YoY to 1.89bn
- **Q1-Q3 adjusted non-IFRS GPM**: 42.8%, improved by 1.6pts YoY due to FX impact
- **Q1-Q3 revenue from new modalities growth**: 35% YoY, contributing 25.9% of revenue

### Discovery Biology

- One of the largest discovery biology enabling platforms with ~3,000 experienced scientists globally (across 9 sites in China, the US and Germany), covering all stages of drug discovery and all major therapeutic areas
- Focused on improving capabilities related to new modalities. Number of customers and projects served by our nucleic acid platform continued to increase. Cumulatively, we have provided services to **130+** customers, and successfully delivered **800+** projects since 2021

### Comprehensive Screening Platform

- Early discovery screening platform integrating multi-technologies (HTS, DEL, ASMS, FBDD, CADD, etc.) and analysis capabilities of multi-dimensional databases, provides extensive and in-depth services to customers
- In Q3 2023, launched the automated high-throughput protein production in Suzhou, and **DELvision**, a new service of chemical-proteome database to bridge the gap between small molecule chemical space and proteomics. Through accumulation of the eminent experimental data, DELvision empowers customers to effectively decipher the mechanism of protein-small molecule interactions
- In Q1-Q3 2023, continued to generate downstream opportunities and contributed **20%+** of the Company’s new customers

#### Revenue

<table>
<thead>
<tr>
<th></th>
<th>Q1-Q3 2022</th>
<th>Q1-Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q3</td>
<td>0.69</td>
<td>0.66</td>
</tr>
<tr>
<td>H1</td>
<td>1.09</td>
<td>1.23</td>
</tr>
</tbody>
</table>

Revenues grew by 6.5% YoY from 1.78bn to 1.89bn, driven by strong growth in the new modalities business.

#### Adjusted Non-IFRS Gross Profit

<table>
<thead>
<tr>
<th></th>
<th>Q1-Q3 2022</th>
<th>Q1-Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q3</td>
<td>0.73</td>
<td>0.81</td>
</tr>
<tr>
<td>H1</td>
<td>0.44</td>
<td>0.51</td>
</tr>
</tbody>
</table>

Adjusted Non-IFRS Gross Profit margin improved by 10.7% YoY from 41.1% to 42.8%.

GPM @ CER: 41.7% Q1-Q3 2022, 41.1% Q1-Q3 2023
WuXi ATU: CTDMO Business Model Drives Growth

Financial Performance

- Q3 revenue grew **2.7%** YoY to **0.31bn**
- Q1-Q3 revenue grew **11.6%** YoY to **1.03bn**
- Q1-Q3 adjusted non-IFRS GPM -6.1%, improved by **0.4pts** YoY due to FX impact

Pipeline & Progress of Commercial Projects

- Focused on improving our integrated CTDMO enabling platform, providing development, testing & manufacturing services for **68** projects, including **7** Phase III projects (2 projects in BLA review stage, and **2** projects in BLA preparation stage), **9** Phase II projects, and **52** preclinical and Phase I projects
- Supported a client to complete BLA filing for a TIL product with FDA, the **world’s first innovative TIL-based therapy**, and facilities in Philadelphia (U.S.) successfully passed the FDA pre-license inspection (PLI)
- Supported a client to file BLA for the LVV used in a CAR-T product, and became the **first CGT CDMO in China to pass CFDI LVV on-site inspection**. We expect our customers will obtain approval of their products in Q4 2023
- Completed the technology transfer to manufacture a blockbuster commercial CAR-T product; process performance qualification is now in progress, and is expected to file pre-approval submission (PAS) to FDA in H1 2024
- In June 2023, signed an LVV manufacturing contract used in a commercial CAR-T product, **expected to start manufacturing in H1 2024**

<table>
<thead>
<tr>
<th>Revenue</th>
<th>Adjusted Non-IFRS Gross Profit</th>
</tr>
</thead>
<tbody>
<tr>
<td>RMB billion</td>
<td>RMB billion</td>
</tr>
<tr>
<td>Q1-Q3 2022</td>
<td>Q1-Q3 2022</td>
</tr>
<tr>
<td>Q3</td>
<td>0.31</td>
</tr>
<tr>
<td>H1</td>
<td>0.62</td>
</tr>
<tr>
<td>Q1-Q3 2022</td>
<td>0.92</td>
</tr>
<tr>
<td>Q1-Q3 2023</td>
<td>1.03</td>
</tr>
</tbody>
</table>

**Note:** 1. CFDI, Center for Food and Drug Inspection of NMPA.

[Diagram showing financial performance and pipeline progress]
WuXi ATU: Growing Pipeline on Our Globally Integrated CTDMO Platform

- **Gene Therapies**
  - AAV | LVV | TESSA

- **Cell Therapies**
  - CAR-T | TIL | MSC Cells

**Testing**

**Fonts**

- **US | EU | CN**

- **US**
- **EU**
- **CN**

- **Preclinical & Phase I**
  - 52 projects

- **Phase II**
  - 9 projects

- **Phase III**
  - 7 projects

- **Commercial**

- **To come starting in Q4 2023**

**Provided globally integrated CTDMO services to** Cell & Gene Therapies product development

- **2 projects are in BLA review stage**
- **2 projects are in BLA preparation stage**
WuXi DDSU: the First Year to Receive NDA Approval of New Drugs Developed for Customers; Breakthrough to Receive the First Royalty Income

Financial Performance
- Q3 revenue declined 31.2% YoY to 0.15bn
- Q1-Q3 revenue declined 26.9% YoY to 0.49bn; achieve the breakthrough to receive the first royalty income
- Q1-Q3 adjusted non-IFRS GPM 31.6%, improved by 3.5pts YoY mainly thanks to favorable project mix

NDA Approval
- In Q1-Q3 2023, 2 new drugs developed for our customers have obtained NMPA approvals, including one for COVID-19 infection treatment and the other for tumor treatment; 2 new drug candidates in NDA review stage
- In Q3 2023, continued to receive the royalty income of the 2 approved new drugs from customers. Royalty income is estimated to grow at 50%+ CAGR over the next 10 years as more and more products get commercialized by DDSU customers

Project Pipeline
- In Q1-Q3 2023, supported customers to file INDs for 15 drug candidates and obtained 19 Clinical Trial Approvals (CTAs)
- Cumulatively submitted 187 IND filings and obtained 163 CTAs, with 2 projects receiving NDA approvals, 2 project in NDA review stage, 5 in Phase III, 29 in Phase II, and 70 in Phase I
- 17 new modality projects covering peptide/PDC, PROTAC® and oligo. 2 projects entered clinical stage, some projects have filed INDs, and multiple projects expected to file INDs in 2023

Revenue
- RMB billion
  - Q3 0.67
  - H1 0.46
  - Q1-Q3 2022 0.22
  - Q1-Q3 2023 0.15
  - Q1-Q3 2022 -31.2%
  - Q1-Q3 2023 -26.9%
  - Q1-Q3 2022 -24.9%

Adjusted Non-IFRS Gross Profit
- RMB billion
  - Q3 0.19
  - H1 0.14
  - Q1-Q3 2022 0.05
  - Q1-Q3 2023 0.05
  - Q1-Q3 2022 -6.1%
  - Q1-Q3 2023 +6.1%
  - Q1-Q3 2022 +31.6%
  - Q1-Q3 2023 -17.8%

Note: PROTAC® is a registered trademark of Arvinas Operations, Inc., and is used under license.
3. Financial Performance
Financial Performance

### Revenue

<table>
<thead>
<tr>
<th>Year</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
<th>2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>RMB MM</td>
<td>9,614</td>
<td>12,872</td>
<td>16,535</td>
<td>22,902</td>
<td>39,355</td>
</tr>
</tbody>
</table>

CAGR: 42.2%

Q1-Q3 2022: 28,395
Q1-Q3 2023: 29,541

### Adjusted Non-IFRS Gross Profit

<table>
<thead>
<tr>
<th>Year</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
<th>2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>RMB MM</td>
<td>3,830</td>
<td>5,155</td>
<td>6,670</td>
<td>8,704</td>
<td>15,228</td>
</tr>
</tbody>
</table>

CAGR: 41.2%

Q1-Q3 2022: 10,991
Q1-Q3 2023: 12,511

### Adjusted Non-IFRS Net Profit Attributable to Owners of the Company

<table>
<thead>
<tr>
<th>Year</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
<th>2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>RMB MM</td>
<td>2,261</td>
<td>1,855</td>
<td>2,960</td>
<td>5,097</td>
<td>8,814</td>
</tr>
</tbody>
</table>

CAGR: 40.5%

Q1-Q3 2022: 7,378
Q1-Q3 2023: 8,076

### Note:
If the sum of the data above is inconsistent with the total, it is caused by rounding.
Note: If the sum of the data above is inconsistent with the total, it is caused by rounding.
Segment Adjusted Non-IFRS Gross Profit

**WuXi Chemistry**

<table>
<thead>
<tr>
<th></th>
<th>Q1-Q3 2022</th>
<th>Q1-Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>RMB MM</td>
<td>8,576</td>
<td>9,717</td>
</tr>
<tr>
<td>%</td>
<td>41.2%</td>
<td>45.7%</td>
</tr>
</tbody>
</table>

Q3: 3,262 +10.8% 3,614
H1: 5,314 +14.9% 6,103

**WuXi Testing**

<table>
<thead>
<tr>
<th></th>
<th>Q1-Q3 2022</th>
<th>Q1-Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>RMB MM</td>
<td>1,539</td>
<td>1,875</td>
</tr>
<tr>
<td>%</td>
<td>36.8%</td>
<td>38.6%</td>
</tr>
</tbody>
</table>

Q3: 612 +15.4% 707
H1: 927 +26.1% 1,168

**WuXi Biology**

<table>
<thead>
<tr>
<th></th>
<th>Q1-Q3 2022</th>
<th>Q1-Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>RMB MM</td>
<td>732</td>
<td>810</td>
</tr>
<tr>
<td>%</td>
<td>41.1%</td>
<td>42.8%</td>
</tr>
</tbody>
</table>

Q3: 288 +4.0% 299
H1: 444 +15.1% 511

**WuXi ATU**

<table>
<thead>
<tr>
<th></th>
<th>Q1-Q3 2022</th>
<th>Q1-Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>RMB MM</td>
<td>5,314</td>
<td>6,103</td>
</tr>
<tr>
<td>%</td>
<td>28.1%</td>
<td>31.6%</td>
</tr>
</tbody>
</table>

Q3: 189 +6.1% 155
H1: 140 -26.2% 103

**WuXi DDSU**

<table>
<thead>
<tr>
<th></th>
<th>Q1-Q3 2022</th>
<th>Q1-Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>RMB MM</td>
<td>3,262</td>
<td>3,607</td>
</tr>
<tr>
<td>%</td>
<td>38.6%</td>
<td>36.8%</td>
</tr>
</tbody>
</table>

Q3: 49 +10.7% 41
H1: 140 -17.8% 126

Note: If the sum of the data above is inconsistent with the total, it is caused by rounding.
## Adjusted Non-IFRS Net Profit

<table>
<thead>
<tr>
<th>RMB Million</th>
<th>Q1-Q3 2022</th>
<th>Q1-Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Net profit attributable to the owners of the Company</strong></td>
<td>7,378</td>
<td>8,076</td>
</tr>
<tr>
<td><strong>Add:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Share-based compensation expenses</td>
<td>503</td>
<td>481</td>
</tr>
<tr>
<td>Issuance expenses of convertible bonds</td>
<td>1</td>
<td>0.3</td>
</tr>
<tr>
<td>Fair value gains from derivative component of convertible bonds</td>
<td>(617)</td>
<td>(40)</td>
</tr>
<tr>
<td>Foreign exchange related gains</td>
<td>(366)</td>
<td>(355)</td>
</tr>
<tr>
<td>Amortization of acquired intangible assets from merge and acquisition</td>
<td>43</td>
<td>43</td>
</tr>
<tr>
<td>Non-financial assets impairment</td>
<td>-</td>
<td>43</td>
</tr>
<tr>
<td><strong>Non-IFRS net profit attributable to the owners of the Company</strong></td>
<td>6,942</td>
<td>8,249</td>
</tr>
<tr>
<td><strong>Add:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Realized and unrealized gains from venture capital investments</td>
<td>(170)</td>
<td>(75)</td>
</tr>
<tr>
<td>Realized and unrealized share of losses (gains) from joint ventures</td>
<td>0.4</td>
<td>(7)</td>
</tr>
<tr>
<td><strong>Adjusted non-IFRS net profit attributable to the owners of the Company</strong></td>
<td>6,772</td>
<td>8,167</td>
</tr>
</tbody>
</table>

Note: If the sum of the data above is inconsistent with the total, it is caused by rounding.
Continued Growth of FCF Driven by Business Growth & Operating Efficiency

Q1-Q3 2023 Operating Cash Flow Grew Strongly by 32.5% YoY; Continued to Invest in New Capacities & New Capabilities

RMB MM

Note: Capital expenditure includes purchase of property, plant and equipment, other intangible assets, prepaid lease payments and other long-term expenses.
4. Growth Outlook
### Q4 and Full Year 2023 Revenue Forecast

<table>
<thead>
<tr>
<th>Quarter</th>
<th>2022 Revenue</th>
<th>2023E Revenue</th>
<th>Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q1 22</td>
<td>8.5 RMB billion</td>
<td>9.0 RMB billion</td>
<td>+16.9%</td>
</tr>
<tr>
<td>Q2 22</td>
<td>9.3 RMB billion</td>
<td>9.9 RMB billion</td>
<td>+39.5%</td>
</tr>
<tr>
<td>Q3 22</td>
<td>10.6 RMB billion</td>
<td>10.7 RMB billion</td>
<td>+15.7%</td>
</tr>
<tr>
<td>Q4 22</td>
<td>11.0 RMB billion</td>
<td>10.6-11.0 RMB billion</td>
<td>+29-34%</td>
</tr>
</tbody>
</table>

In Q4 2023, revenue will all come from non-COVID-19 commercial projects. Without COVID-19 commercial projects, we expect Q4 revenue to exceed RMB 10 billion for the first time:

- WuXi Chemistry D&M revenue will continue strong growth momentum, and accelerate growth on top of Q1-Q3
- Due to lower than expected demand of early-stage drug discovery services, revenues from certain lab service related business will be significantly below budget
2023 Outlook

1. The Company sees lower than expected demand of early-stage drug discovery services in Q4, which will be significantly below budget. **Therefore, we adjust 2023 revenue growth from 5-7% to 2-3%; excluding COVID-19 commercial projects, revenue growth from 29-32% to 25-26%.**

2. Thanks to FX impact and efficiency improvements, **adjusted non-IFRS GPM expects to be up ~0.5pts and reach 41.7-42.1%; with further improved operating efficiency, adjusted non-IFRS net profit will exceed RMB 10 billion for the first time.**

3. Resulting from our unique CRDMO & CTDMO business model, better asset utilization and efficiency improvements, **free cash flow expects to be up and reach RMB 4.5-5.0 billion, which will be over 17 times as compared to last year.**

4. Due to lower than expected growth, the management team **proactively proposed to terminate the 2023 H share incentive plan, repurchase and cancel 15,467,500 H shares, representing ~0.52% of the Company's total share capital (worth of HKD ~1.3 billion¹). This has been unanimously approved by the Company's Board of Directors.**

---

Note: 1. Value based on the actual purchased price.

Disclaimer: This presentation may contain certain “forward-looking statements” which are not historical facts, but instead are predictions about future events based on our beliefs as well as assumptions made by and information currently available to our management. Although we believe that our predictions are reasonable, future events are inherently uncertain and our forward-looking statements may turn out to be incorrect.